Tokyo (JCN) Dec 27, 2005 - Kissei Pharmaceutical and JCR Pharmaceuticals have jointly announced that they have singed a joint research agreement for JR-013, a compound candidate discovered by JCR Pharmaceuticals. JR-013 is a drug candidate for the treatment of renal anemia based on recombinant human erythropoietin.
